242 related articles for article (PubMed ID: 27506141)
1. Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.
Westphal R; Sumiyoshi A; Simmons C; Mesquita M; Wood TC; Williams SC; Vernon AC; Cash D
Neuroscience; 2016 Oct; 334():166-179. PubMed ID: 27506141
[TBL] [Abstract][Full Text] [Related]
2. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
[TBL] [Abstract][Full Text] [Related]
3. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
4. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
5. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
6. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
7. 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
Kondoh T; Bannai M; Nishino H; Torii K
Exp Neurol; 2005 Mar; 192(1):194-202. PubMed ID: 15698634
[TBL] [Abstract][Full Text] [Related]
8. Time course study of fractional anisotropy in the substantia nigra of a parkinsonian rat model induced by 6-OHDA.
Zhang W; Zhang L; Liu L; Wang X
Behav Brain Res; 2017 Jun; 328():130-137. PubMed ID: 28390876
[TBL] [Abstract][Full Text] [Related]
9. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
10. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
Fine JM; Forsberg AC; Renner DB; Faltesek KA; Mohan KG; Wong JC; Arneson LC; Crow JM; Frey WH; Hanson LR
Brain Res; 2014 Jul; 1574():96-104. PubMed ID: 24928620
[TBL] [Abstract][Full Text] [Related]
11. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
13. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F
J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909
[TBL] [Abstract][Full Text] [Related]
14. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Lin L; Yan M; Wu B; Lin R; Zheng Z
Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
16. Graded 6-OHDA-induced dopamine depletion in the nigrostriatal pathway evokes progressive pathological neuronal activities in the subthalamic nucleus of a hemi-parkinsonian mouse.
Park SE; Song KI; Kim H; Chung S; Youn I
Behav Brain Res; 2018 May; 344():42-47. PubMed ID: 29452192
[TBL] [Abstract][Full Text] [Related]
17. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Balcioglu A; Zhang K; Tarazi FI
Neuroscience; 2003; 119(4):1045-53. PubMed ID: 12831863
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Meshul CK; Allen C
Synapse; 2000 May; 36(2):129-42. PubMed ID: 10767060
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
20. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
